logo

FDA Calendar

PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.

The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.

Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.

Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
Company Name
Drug
Event
Outcome
Details
Biohaven Pharmaceutical Holding Co Ltd.
(BHVN)
NURTEC ODT (sNDA)
Q2 2021
FDA decision on NURTEC ODT for the preventive treatment of migraine
-
AstraZeneca PLC
(AZN.L, AZN)
FARXIGA (sNDA)
Q2 2021
FDA decision on FARXIGA for the treatment of new or worsening chronic kidney disease in adults with and without type 2 diabetes
-
United Therapeutics Corp
(UTHR)
Tyvaso (sNDA)
Apr 2021
FDA decision on Tyvaso for the treatment of pulmonary hypertension associated with interstitial lung disease
FDA approved Tyvaso for the treatment of pulmonary hypertension associated with interstitial lung disease on Apr.1, 2021-
Pfizer Inc.
(PFE)
LORBRENA (sNDA)
Apr 2021
FDA decision on LORBRENA first-line treatment for people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer
FDA approved LORBRENA as first-line treatment of people with ALK-positive non-small cell lung cancer on Mar.3, 2021-
Supernus Pharmaceuticals, Inc.
(SUPN)
SPN-812 (Resubmitted NDA)
Early Apr 2021
FDA decision on SPN-812 for the treatment of ADHD in pediatric patients
FDA approved SPN-812 under brand name Qelbree for pediatric ADHD patients on Apr.3, 2021-
Pfizer Inc.
(PFE)
Abrocitinib (NDA)
Apr 2021
FDA decision on Abrocitinib for the treatment of moderate to severe atopic dermatitis (AD) in patients 12 and older.
On Apr.7, 2021, the FDA notified the company that the decision date has been extended by months to early Q3, 2021-
Mayne Pharma Group Limited
(MAYNF.OB)
Estelle (NDA)
Apr 2021
FDA decision on Estelle, a contraceptive product
-
AstraZeneca PLC
(AZN.L, AZN)
Tralokinumab (BLA)
Q2 2021
FDA decision on Tralokinumab for the treatment of adults with moderate-to-severe atopic dermatiti
-
ACADIA Pharmaceuticals Inc
(ACAD)
NUPLAZID (sNDA)
04/03/2021
FDA decision on NUPLAZID for the treatment of hallucinations and delusions associated with dementia-related psychosis
FDA issued a Complete Response Letter for NUPLAZID for the treatment of hallucinations and delusions associated with dementia-related psychosis on Apr.5, 2021-
Regeneron Pharmaceuticals
(REGN)
Praluent (sBLA)
04/04/2021
FDA decision on the expanded use of Praluent for homozygous familial hypercholesterolemia (HoFH) in adults
-

ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.

Buy this Content


pfizer covid19 010621 19apr21 Pfizer Inc. and BioNTech SE Monday announced that they will supply an additional 100 million doses of COMIRNATY, the companies' COVID-19 vaccine, to the 27 European Union member states in 2021. The agreement follows the European Commission's decision to exercise its option to purchase an additional 100 million doses under its expanded Advanced Purchase Agreement signed on February 17.
Bristol Myers Squibb Co. (BMY) Wednesday said the European Commission has approved its drug nivolumab in combination with cabozantinib as a treatment for patients with advanced renal cell carcinoma. The New York-based pharmaceutical company said the EC's decision was based on results from a late-stage...
fda jnj ema 041521 The European Medicines Agency Wednesday said that it believes the benefits of Johnson & Johnson's (JNJ) COVID-19 vaccine outweigh the risks of side effects. The regulator issued the statement following a temporary halt of the vaccine in the US after reports of extremely rare blood clotting. The other...
Read More
Pfizer Inc. and BioNTech SE Monday announced that they will supply an additional 100 million doses of COMIRNATY, the companies' COVID-19 vaccine, to the 27 European Union member states in 2021. The agreement follows the European Commission's decision to exercise its option to purchase an additional 100 million doses under its expanded Advanced Purchase Agreement signed on February 17.
74312 new coronavirus cases were reported in the United States on Thursday, taking the national total to 31495652. This is higher than the 7-day average of 70514. 909 new deaths were reported in the country on the same day. With this, the COVID death toll in the U.S. increased to 565289, according to the latest data from Johns Hopkins University. The 7-day average of COVID deaths is 750. Washing
75,267 new coronavirus cases were reported in the United States on Tuesday, taking the national total to 31,421,367. The number of new cases is higher than the 7-day average of 71,511. 932 new deaths were reported in the country on the day. With this, the COVID death toll in the U.S. increased to 564,402, according to the latest data from Johns Hopkins University. The 7-day average of COVID deaths is 764.
Read More